Minimally Invasive Surgical Devices
Oct 27, 2022
FDA Approval to DePuy TELIGEN System; FDA Breakthrough Device Designation for the EndoStim System; GE and Accuray Announces Collaboration; Mentice and Acandis Announces a Three-Year Agreement; Indigo Diabetes Enrolled First Participant in the Shine Clinical Trial; FDA IDE Approval to MedAlliance’s SELUTION SLR
DePuy Synthes Received FDA Approval for TELIGEN™ System On October 20, 2022, DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopedics portfolios in the world that helps heal and restore movement for the millions of patients, announced that ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
